Will GLP-1s work for monogenic obesity?

Question

Hello doctor,

I am considering metabolic surgery, but my situation is more complex than typical obesity. I have been diagnosed with monogenic obesity due to a rare MC4R (melanocortin 4 receptor) gene variant. I have heard that certain gene mutations can reduce the effectiveness of procedures like gastric bypass or sleeve gastrectomy.

Does this genetic factor impact expected outcomes with these surgeries?
Are there specific procedures that work better for individuals with MC4R-related obesity?
Also, how do newer medications like GLP-1 (glucagon-like peptide-1) receptor agonists fit into this picture? Would a combination of surgery and medication be an option?

Please help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I have read your query and can understand your concern.

Monogenic obesity, particularly involving variants in the MC4R (melanocortin-4 receptor) gene, presents distinct challenges in the management of obesity, especially regarding treatment responsiveness and long-term outcomes. Below is a detailed overview:

Overview of MC4R-related obesity:
1. MC4R mutations are the most common cause of monogenic obesity.
2. These variants disrupt satiety signaling, leading to early-onset, severe obesity and persistent hyperphagia (increased appetite).
3. The condition is often resistant to conventional weight-loss strategies.
Impact on bariatric surgery (RYGB vs. sleeve gastrectomy):
1. Patients with MC4R mutations can still achieve meaningful weight loss through bariatric surgery, though results may be attenuated compared to non-genetic forms of obesity.
2. Roux-en-Y Gastric Bypass (RYGB) is often more effective than Sleeve Gastrectomy, likely due to greater effects on gut hormones involved in appetite regulation (for example, GLP-1, PYY).
3. Despite potentially reduced weight loss, metabolic improvements (for example, insulin sensitivity, lipid profile) are typically observed.
Surgical considerations for MC4R-related obesity:
1. RYGB is generally favored in monogenic obesity due to its hormonal impact and potential for better appetite control.
2. Outcomes can vary depending on the specific mutation and its functional impact, highlighting the need for individualized treatment planning.
3. Role of Pharmacotherapy (GLP-1 agonists and Setmelanotide):
4. GLP-1 receptor agonists (for example, Semaglutide, Liraglutide) have shown some efficacy in MC4R-related obesity, though the response may be partial.
5. Setmelanotide, a melanocortin receptor agonist targeting the MC4R pathway directly, is approved for certain rare genetic obesity syndromes and may offer a more targeted option in select patients.
6. Combining medications with surgery may enhance outcomes in difficult-to-treat cases.
Diagnostic and preoperative considerations:
1. Probable diagnosis: Monogenic obesity due to MC4R mutation, with metabolic criteria supportive of bariatric eligibility.
Recommended investigations:
1. Genetic confirmation of the MC4R variant (if not already done).
2. Comprehensive metabolic panel (HbA1c, lipid profile, liver enzymes).
3. Nutritional and psychological assessment before surgery.
Differential diagnoses to consider:
1. Other forms of monogenic or syndromic obesity (for example, leptin pathway mutations).
2. Polygenic obesity with early onset.
Suggested treatment plan:
1. Primary intervention: Roux-en-Y Gastric Bypass (RYGB).
2. Adjunct therapies: GLP-1 receptor agonists or Setmelanotide (if eligible).
3. Supportive care: Lifestyle intervention (nutrition, physical activity, behavioral therapy).
4. Follow-up: Long-term endocrinology and bariatric care for ongoing metabolic monitoring and support.

I hope this answers your query.

Please let me know if I can assist you further.

Thank you.